Data Insights

Risk adjusted net present value: What is the current valuation of Daiichi Sankyo's Patritumab deruxtecan?

Patritumab deruxtecan is a monoclonal antibody conjugated commercialized by Daiichi Sankyo, with a leading Phase III program in Non-Small Cell...

Net Present Value Model: Daiichi Sankyo Co Ltd's Patritumab deruxtecan

Data Insights

Patritumab deruxtecan by Daiichi Sankyo for Metastatic Breast Cancer: Likelihood of Approval

Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Metastatic Breast Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Patritumab Deruxtecan in Metastatic Breast Cancer

Data Insights

Patritumab deruxtecan by Daiichi Sankyo for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According...

Likelihood of Approval and Phase Transition Success Rate Model - Patritumab Deruxtecan in Triple-Negative Breast Cancer (TNBC)

Data Insights

Patritumab deruxtecan by Daiichi Sankyo for Non-Small Cell Lung Cancer: Likelihood of Approval

Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase III for Non-Small Cell Lung Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Patritumab Deruxtecan in Non-Small Cell Lung Cancer

Data Insights

Patritumab deruxtecan by Daiichi Sankyo for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Human Epidermal Growth Factor Receptor...

Likelihood of Approval and Phase Transition Success Rate Model - Patritumab Deruxtecan in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)

Data Insights

Patritumab deruxtecan by Daiichi Sankyo for Gastric Cancer: Likelihood of Approval

Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Gastric Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Patritumab Deruxtecan in Gastric Cancer

Data Insights

Patritumab deruxtecan by Daiichi Sankyo for Metastatic Melanoma: Likelihood of Approval

Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Metastatic Melanoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Patritumab Deruxtecan in Metastatic Melanoma

Data Insights

Patritumab deruxtecan by Daiichi Sankyo for Hypopharyngeal Cancer: Likelihood of Approval

Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Patritumab Deruxtecan in Hypopharyngeal Cancer

Data Insights

Patritumab deruxtecan by Daiichi Sankyo for Laryngeal Cancer: Likelihood of Approval

Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Laryngeal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Patritumab Deruxtecan in Laryngeal Cancer

Data Insights

Patritumab deruxtecan by Daiichi Sankyo for Oropharyngeal Cancer: Likelihood of Approval

Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Oropharyngeal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Patritumab Deruxtecan in Oropharyngeal Cancer

Data Insights

Patritumab deruxtecan by Daiichi Sankyo for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction....

Likelihood of Approval and Phase Transition Success Rate Model - Patritumab Deruxtecan in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

Patritumab deruxtecan by Daiichi Sankyo for Oral Cavity (Mouth) Cancer: Likelihood of Approval

Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Oral Cavity (Mouth) Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Patritumab Deruxtecan in Oral Cavity (Mouth) Cancer

Data Insights

Patritumab deruxtecan by Daiichi Sankyo for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Head And Neck Squamous Cell...

Likelihood of Approval and Phase Transition Success Rate Model - Patritumab Deruxtecan in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

Patritumab deruxtecan by Daiichi Sankyo for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase I for Squamous Non-Small Cell Lung Cancer....

Likelihood of Approval and Phase Transition Success Rate Model - Patritumab Deruxtecan in Squamous Non-Small Cell Lung Cancer

Data Insights

Patritumab deruxtecan by Daiichi Sankyo for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Human Epidermal Growth Factor Receptor...

Likelihood of Approval and Phase Transition Success Rate Model - Patritumab Deruxtecan in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

Data Insights

Patritumab deruxtecan by Daiichi Sankyo for Cervical Cancer: Likelihood of Approval

Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Cervical Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Patritumab Deruxtecan in Cervical Cancer

Data Insights

Patritumab deruxtecan by Daiichi Sankyo for Endometrial Cancer: Likelihood of Approval

Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Endometrial Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Patritumab Deruxtecan in Endometrial Cancer

Data Insights

Patritumab deruxtecan by Daiichi Sankyo for Fallopian Tube Cancer: Likelihood of Approval

Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Fallopian Tube Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Patritumab Deruxtecan in Fallopian Tube Cancer

Data Insights

Patritumab deruxtecan by Daiichi Sankyo for Acral Lentiginous Melanoma: Likelihood of Approval

Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Acral Lentiginous Melanoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Patritumab Deruxtecan in Acral Lentiginous Melanoma

Data Insights

Patritumab deruxtecan by Daiichi Sankyo for Peritoneal Cancer: Likelihood of Approval

Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Peritoneal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Patritumab Deruxtecan in Peritoneal Cancer